biopharmx corpor bpmx buy pt reduc pt share dilut stock reverse-split share
inc buy pt solid reduc pt due valuat maintain buy base
anticip stronger analyst michael diana full summari
reneuron group plc rene buy pt build poc data cell therapi retin pigmentosa rais
pt analyst jason mccarthi ph full summari
inc buy pt lower pt like weak traffic high beef cost
inc hold pt labor cost add margin pressur mute ep growth outlook despit
solid top line lower pt maintain hold analyst stephen anderson full summari
intevac inc ivac hold beat slightli confid ivac near inflect point remain
potbelli corpor buy pt weak comp anticip still expect gradual comp margin rebound
 maintain buy pt analyst stephen anderson full summari
pareteum corpor buy pt preview rais estim backlog strength new win
western digit corpor buy pt multipl data point suggest bottom reiteraitng buy
normal ep power analyst nehal chokshi full summari
cerecor inc buy pt updat posit safeti profil pk data analyst carolin
inc buy pt posit improv energi market expand offer maintain buy pt
corpor event call maxim salesperson inform
emerg therapi sickl cell diseas dinner boston dr martin steinberg wed may
corp ndr lo angel ceo sherif foda wed may
natur ga servic cover sullivan ndr nyc ceo steve taylor wed may
maxim group industri confer nyc mg sgbx
host sullivan thu jun
inc cover ndr dalla svp cfo taylor vice-president financ
investor relat treasuri mika ware mon may
corpor cover ndr milwauke evp cao cfo mark wolfing
svp financ robert verostek tue may
inc cover ndr boston cfo golder vice-president
boxlight corpor boxl cover klee ndr nyc presid michael pope wed-thu may
identiv inc cover chokshi ndr nyc ceo stephen humphrey cfo sandra wallach mon
net inc uep cover klee ndr nyc group vice-president ir corpor develop
manag director ceo netpay dhruv chopra tue may
pareteum corpor cover klee ndr chicago presid deni mccarthi corpor
develop investor relat michael bloom mon jun
pareteum corpor cover klee ndr dalla presid deni mccarthi corpor
develop investor relat michael bloom tue jun
annual silicon valley bu tour host chokshi tue
solid reduc pt due valuat maintain
buy base anticip stronger
result materi consensu adjust ebitda
ep modestli consensu revenu revenu miss
intent slow loan origin new credit
model readi earn beat result mainli higher
gross margin reflect strong credit qualiti lower custom acquisit
guidanc anticip slower flattish revenu prior
roll-out new credit model faster newli introduc
estim reflect continu pace growth
lower price target base new
adjust ebitda estim price target reflect signific
discount ev/ebitda valuat best close compar
 buy view discount justifi
given enova much longer consist earn histori
profit sinc format share
oversold sinc earn miss see chart left
result summari april post-clos report result
materi consensu adjust ebitda versu consensu
estim ep versu consensu
estim modestli consensu revenu versu
consensu estim revenu miss
intent slow loan origin new credit model readi
earn beat result mainli stronger gross margin gross
margin versu better credit qualiti result lower
loan loss provis effici market result lower
versu due season best comparison
year-ago quarter inde manag lower target rang
start
credit qualiti regard credit qualiti stabl solid loan loss
provis revenu compar loan loss reserv
loan compar smaller reserv need
improv credit qualiti past-du loan loan compar
introduc estim revenu adjust ebitda
ep manag chang guidanc
lower revenu estim toward low-end guidanc
page updat earn model
lower price target view ev/ebitda multipl
best valuat metric fintech on-line lend peer share
current trade ev/ebitda multipl base new
estim regard on-line non-prim competitor best
close compar price target ev/ebitda multipl
would prior target versu enova regard
discount enova reason time expect third year
posit net incom wherea enova profit sinc
format
maintain buy rate next four quarter expect stock price
appreci price target
click full note
preview rais estim backlog strength
ahead result due tue rais revenu estim
y/i adjust ebitda
vs strength backlog build result includ artilium
acquir oct partial result ipass acquir feb
pareteum cloud-bas solut reson well custom
evidenc y/i same-stor sale connect growth
prior quarter benefit greater demand thing connect
project revenu rise prior adjust
ebitda rise prior project revenu
growth ebitda growth
upsid estim compani abl continu convert
three-year contract revenu backlog recent rate win new
much improv balanc sheet gener support organ
growth without need rais capit
compel valuat trade revenu valu
stock base revenu
rais estim transit much larger
profit compani reson custom compel offer
network connect relat servic one-stop-shop solut benefit
restructur new offer along acquisit transit
attract fast-grow saa compani compani gone declin
sale loss top line growth
acquisit ipass artilium compani expand offer valu
proposit custom rais revenu estim
vs consensu y/i adjust ebitda
consensu revenu come saa
project high growth rate profit expect
revenu grow respect adjust ebitda
rise even though
model high growth rate upsid estim compani
continu convert three-year contract revenu backlog
rate produc use reflect greater challeng compani
scale also could see upsid estim new win like given
compani compel offer project turn posit
per share per share
transform larger profit saa commun
servic provid expect stock get revalu higher level
current trade revenu estim price target base
revenu estim peer group saa commun servic
provid trade revenu use lower multipl peer given earli
stage turnaround argu market yet realiz transform
compani creat compel buy opportun rate also take account
posit tailwind associ trend thing get connect
custom look simplifi one-stop-shop cloud solut final note
stock under-own institut investor total ownership
could creat catalyst hit screen high growth profit
click full note
multipl data point suggest bottom
reiteraitng buy normal ep power
result in-lin normal write-down relat dram
reiter buy rate normal ep power
result in-lin normal write-down relat dram
y/i q/q in-lin guidanc
consensu estim non-gaap ep guidanc rang
includ charg ep larg relat
write-down dram inventori q/q multi-chip-modul
dram nand flash chip stack within packag exclud would
result non-gaap ep exclud impact inventori write-
estim nand flash gm estim though still
dec level note q/q nand flash
gm declin normal basi compar favor triangul
q/q downtick nand flash gm mu feb anoth major
posit hdd revenu flat q/q higher asp margin data
center hdd unit q/q overal hdd unit q/q result better
expect high capac enterpris hdd demand result mix shift higher
margin data center hdd hdd gm q/q manag also
note current capac enterpris hdd demand continu equat
pull-in return demand cloud servic provid manag expect
high capac enterpris exabyt eb shipment y/i vs quarter
ago guidanc low
guid jun revenu flat q/q /- in-lin
consensu ep flat q/q though consensu gm
vs gm manag note expect hdd
gm continu trend q/q impli nand flash gm declin
q/q basi believ latter impli assert conserv given nand
flash price shown better trajectori month april vs
aggress reduc nand flash suppli peer reduct vs
peer result less build-up inventori wdc balanc sheet
well manag note channel inventori start come wherea
peer note inventori build channel favor restructur
debt coven without increas interest rate show strong appetit
like underpin confid normal earn power well current
fundament result near alreadi bottom
reiter buy rate normal ep power price
target jun estim larg unchang result
jun guidanc larg in-lin expect also
continu believ wdc sndk divis remain cost competit
condit extend downcycl name yangtz memori technolog becom
cost competit transpir downcycl continu
believ current downcycl short-liv normal earn
power remain rang see septemb note detail
strongli believ durabl wdc earn power albeit cyclic volatil
continu exist ep compound-annual-growth-rate likelihood cycl share
trade normal earn modest discount due
volatil standard util across cover compani
price target unchang base use multipl
jun ep margin prior estim given
durabl earn power growth potenti upsid price
target repres rel current trade price emphat reiter
buy rate
click full note
posit improv energi market expand
result schedul monday may expect revenu
adjust ebitda sequenti declin respect due
runoff nobl corp ne nr contract fulli behind
end
current forecast revenu ebitda full year
estim like prove conserv compani could outperform
ad new busi fast growth iot si segment
project signific improv
remain posit compani abil gain market share
custom core energi market base broader offer
competitor includ iot segment ad
acquisit
system integr si segment revamp improv
focu profit recur revenu strong pipelin contract
maintain buy rate price target base
rnet diversif strategi improv core energi end market support
posit view stock expect revenu y/
prior quarter due run remain nobl
corp -relat rig project adjust ebitda y/i expect
sequenti declin manag commun servic factor run-off
lost contract expect strength si iot expect result
back-half load due soft manag servic higher legal fee
believ compani addit offer move applic stack
cybersecur machin learn video sensor provid compel suit
offer enabl compani gain market share also encourag
disciplin approach system integr segment result
grow backlog better profit focu project creat recur
revenu project revenu declin rise
believ project could prove conserv includ new win
manag commun servic modest growth assumpt
 iot segment activ custom per site value-
ad app expect margin improv project adjust ebitda grow
expect get contribut
compani build-out lte network gulf mexico longer term
believ signific earn power gross margin current run
close half prior peak
balanc sheet cash flow avail liquid support growth
potenti litig liabil compani post improv oper cash flow
point improv effort collect note capit
expenditur current elev relat due build-out lte network
gulf mexico estim complet project total cost cost
relat acquir facil lafayett louisiana expect capital-expenditure elev
relat complet activ return normal
per quarter budget capital-expenditure result
model free cash outflow per share posit
per share meanwhil manag set reserv relat
first phase arbitr relat gx inmarsat contract compani adjust
borrow capac adequ liquid even worst-cas
decis rule expect later year second phase arbitr allow
make argument potenti offset amount could reduc
final payment result overhang believ compani unlik pursu
acquisit rest rather focu improv intern perform
cross-sel
stock valuat offset risk worst-cas scenario inmarsat
arbitr view lost first part arbitr inmarsat relat
disput contract purchas capac new gx network base
recognit take pay contract result reserv
repres present valu full contractu oblig gx contract
second part arbitr begin june compani opportun
present potenti offset believ compani could reduc total amount
owe result inmarsat issu delay make offer avail
gx competit newer technolog even lose full
amount end fund debt estim net debt ttm ebitda
scenario stock would trade adjust
ebitda estim still peer compani adjust credit facil
abl fulli fund worst-cas scenario regardless outcom believ
decis case catalyst remov overhang stock
maintain buy rate price target stock current trade
adjust ebitda estim price target base adjust
ebitda peer group energi communications-rel name trade
ebitda contend pullback rnet stock last year reflect declin
oil servic stock price oil concern inmarsat litig
argu unjustifi compani diversifi revenu stream
off-shore custom tend take long-term view addit expect
inmarsat litig end much lower liabil mention
first round arbitr pullback view also overlook compani
valu proposit result compani gain market share note
oper close half prior peak margin signific oper leverag
potenti rate also reflect posit view industri oligopoli structur
compani mainli recur revenu attract end-market growth outlook
click full note
lower pt like weak traffic high
maintain buy rate del though lower price target
ahead releas march result monday may
close
march ep estim unchang vs consensu
reduc june estim vs consensu
decemb ep estim vs
consensu believ higher beef cost hurt margin next
coupl quarter
although lower ep estim vs
consensu model jump ep growth anticip asset sale
franchise sustain comp growth cost save
march ep estim unchang expect post
blend comp vs consensu like mark first time
quarter regist neg comp
reduc june estim
decemb ep estim believ higher beef
cost hurt margin next coupl quarter lower ep
estim reflect higher beef cost shown exhibit wake
extens flood upper plain state toward end like reduc
although lower ep estim model
jump ep growth anticip asset sale franchise sustain comp
growth cost save expect gain driven refranchis
sell company-own restaur restaur
franchise baselin comp growth rang effici
gain compani elev combin solut restaurant-level oper
lower price target still view taco
valuat attract particularli believ refranchis
import catalyst next month share trade
revis ep estim averag sinc compani
ipo well averag quick servic segment revis
price target assum resumpt comp growth averag
next month margin expans gener refranchis
slight acceler new unit growth bia toward higher-margin franchis unit
growth pt base valuat year well two differ valuat
methodolog forward multipl price-to-earnings ev/ebitda
click full note
weak comp anticip still expect gradual comp
margin rebound maintain buy pt
maintain buy rate price target potbelli corpor
ahead releas march result tuesday may
close
maintain march estim loss narrow
consensu loss
howev rais june ep estim though
remain consensu
unchang decemb ep estim vs consensu
reflect rebound comp eventu margin
still expect sharp rebound ep vs consensu
maintain march estim loss estim
comp reflect effect partial feder govern shutdown
januari locat greater washington dc togeth
account pbpb locat colder-than-usu weather
reduc foot traffic chicago mid-west market togeth account
pbpb locat howev comp estim
consensu believ traffic comp rebound solidli march
howev rais june ep estim although
comp estim unchang vs consensu adjust
quarterli ep cadenc reflect shift outlook sg
oper expens relat expand deliveri remain
consensu reflect time shift easter/passov holiday
late earli
unchang decemb ep estim reflect rebound
comp eventu margin company-level initi take hold although
ep estim ep consensu
estim full-year comp vs consensu driven primarili
traffic off-set somewhat check new pick-your-pair menu platform
launch februari
still expect sharp rebound ep vs consensu
anticip addit sustain same-restaur sale growth
expect restaurant-level ebitda margin expans
gain increment off-premis cater deliveri sale moreov estim
oper margin expans aggress
expect compani gain sale leverag invest made late
estim reflect potenti refranchis
believ provid anoth ep growth lever
attract valuat even recent rebound even share
post-earn low late februari share trade
ep estim ipo averag unchang
price target reflect outlook comp rebound
pronounc margin rebound acceler share buyback base
combin two methodolog price-to-earnings ratio target unchang
ep estim forward ev/ebitda ratio target
click full note
labor cost add margin pressur mute ep growth
outlook despit solid top line lower pt maintain
maintain hold rate lower price
target follow releas disappoint march
report pro forma ep estim
street mean blend comp still respect
estim street mean
lower june ep estim vs street
also reduc decemb ep estim vs
street ep estim vs street
expect higher labor cost off-set somewhat
benign food cost outlook expect
ep actual vs maxim street
revenu actual vs maxim street
comp actual blend vs maxim blend street
restaurant-level ebitda margin actual vs maxim
street
oper margin pro forma actual vs maxim street
june to-dat comp actual vs maxim street
revis estim blend
decemb updat guidanc base year
ep manag provid full-year ep guidanc vs maxim pre-
releas street revis ep estim
comp maintain outlook posit same-restaur sale vs pre-releas
estim maxim blend street revis estim
food cost inflat unchang inflat
labor cost inflat increas mid-single-digit inflat
new unit growth unchang net new company-own unit vs
maxim
lower price target reflect chang ep growth outlook
yesterday close share trade forward price-to-earnings
full-servic dine averag though compani five-
year averag expect ep growth averag mid-teen
prior forecast mid-to-high-teen ep growth
reduc forward price-to-earnings multipl target appli downwardli
revis ep estim arriv new price target
correspond forward ev/ebitda ratio compani
five-year averag
click full note
beat slightli confid ivac near
inflect point remain maintain hold rate
beat due higher expect equip upgrad activ result
custom pull demand
revenu growth guidanc midpoint gm guidanc
multipl effort remain play drive ivac inflect high growth
confid ivac near inflect point remain low maintain hold
beat due higher expect equip upgrad activ
result custom pull demand ivac report revenu
y/i slightli ahead guidanc consensu
gm also consensu guidanc
result non-gaap loss per share exclud non-cash tax
benefit better consensu estim
report segment perspect upsid gener thin film equip upgrad
activ vs estim partial off-set photon weaker
expect actual vs estim though believ in-lin
system includ recognit four energi system one lean
system in-lin prior manag commentari
revenu growth guidanc midpoint gm guidanc
maintain march quarter book result total backlog
q/q consist thin film equip backlog
consist lean hdd system energi solar ion system addit
non-system hdd backlog photon backlog manag provid
jun revenu guidanc y/i midpoint emb
expect shipment lean system photon revenu
well midpoint gm guidanc q/q y/i non-
loss per share manag also maintain guidanc
consist total revenu growth y/i backend load revenu
includ thin film equip revenu growth y/i photon
revenu growth least y/i along midpoint gm opex
tax expens includ within thin film equip
revenu estim recognit remain five energi asp
system backlog lean system backlog asp
assumpt one vertex system book asp upgrad
spare vs upgrad given guidanc paramet
 result project revenu jun
prior estim sept dec prior
estim pull thin film equip revenu
result total revenu estim larg maintain
y/i loss per share estim vs prior ep estim
consensu realign estim unchang gm
guidanc vs prior estim
multipl effort remain play drive ivac inflect point high growth
confid ivac near inflect point remain low maintain hold
continu believ odlc film deposit via vertex tool signific
valu smartphon oem evidenc top smartphon oem believ
huawei privat adopt ivac odlc film stack decor color coat
back one high-end smartphon see note also
note program us armi integr visual augment
iva program develop deliveri camera modul
next two year present anoth potenti growth catalyst program success
lead unlock opportun manag discuss
past two year envis time inflect point given
two-year program like iter still least three year away
vertex repres massiv excit opportun believ ivac
best look modest growth though expect
ivac swing back posit earn given perspect
believ hold rate warrant
click full note
reduc pt share dilut stock reverse-split
march bpmx rais net cash share offer
april revers stock split approv regain
complianc certain nyse american continu list standard
april bpmx began trade post revers stock split-adjust
march compani announc complet enrol
phase clinic trial treatment
rosacea remain patient expect complet
treatment end may top-lin data readout still expect
bottom line would continu buyer bpmx even share dilut
revers stock split due larg potenti market two innov
minocyclin product candid remain posit long-term opportun
even though compani yet secur fund necessari conduct pivot
phase studi acn product still look ahead data phase
rosacea trial juli result share offer encourag
compani improv cash posit provid addit runway compani
fund oper potenti clinic trial although rosacea trial timelin
track lower price target share dilut factor
recent equiti rais addit like need addit capit
rais howev continu recommend bpmx due belief minocyclin
candid could transform treatment rosacea acn
revers split april biopharmx announc approv revers
stock split common share ratio split becam effect april
share trade split-adjust basi nyse american
market open april revers stock split primarili effect
regain complianc certain nyse american continu list standard relat
low price per share compani common stock although revers split
often seen posit sign believ compani strong potenti two
main product candid maintain opinion
share offer march biopharmx offer share common
stock investor regist direct offer per share pre-revers split
gross net proce respect januari
fiscal year-end cash cash equival quarterli cash
burn rate roughli net proce offer use advanc
clinic program product develop gener busi purpos
offer close march
compel valuat deriv new price target employ
dcf analysi discount rate perpetu growth rate
click full note
updat posit safeti profil pk data
announc posit data phase trial
phosphoglucomutas defici far favor
safeti profil well-toler seriou advers event
sae view news increment posit pk data expect
follow mid-year set stage efficaci trial
phase trial singl us center safeti toler pharmacokinet
pk studi open-label random single-dos crossov
studi healthi adult volunt dose complet pk data next
compani also begun retrospect studi congenit disord
glycosyl cdg patient treat monosaccharid substrat
replac therapi mannose-phosph isomeras mpi
defici mpi-cdg leukocyt adhes defici type ii ladii
data gather use demonstr safeti efficaci well
reduc number clinic trial agenc may requir
program
ultra-pur oral formul d-galactos treatment
phosphoglucomutas defici d-galactos activ
pharmaceut ingredi api natur monosaccharid found fruit
dairi product use protein glycosyl process carbohydr
februari fda grant cerecor track design
qualifi pediatr diseas prioriti review voucher prv
upon approv sinc two drug get prioriti review prv voucher
prv sold bought anoth compani use anoth indic
defici result rare mutat gene encod
enzym convert
phosphat sourc udp-galactos substrat donat galactos
subunit glycoprotein synthesi patient congenit disord glycosyl
cdg typic present neurolog abnorm includ cognit
defici seizur well cerebellar hypoplasia addit diseas
caus issu organ system across bodi includ hypotonia decreas
muscl tone bleed blood clot issu edema cross eye facial
dysmorph note heart liver also affect patient
treatment option clinician left focu treat symptom possibl
phase trial singl us center safeti toler pharmacokinet studi
pk open-label random single-dos crossov studi healthi
adult volunt dose complet pk data next expect read
summer program evalu util regulatori
pathway substrat replac patient defici
hypothes increas avail udp-galactos repair galactose-defici
click full note
build poc data cell therapi retin
pigmentosa rais pt
reneuron announc addit phase preliminari data cell therapi
retin pigmentosa rp present annual retin cell
gene therapi innov summit first patient continu experi
improv vision acuiti cell reneuron build proof concept
lower risk adjust model rais
price target
effect continu increas time though early-stag small
valu increas efficaci trend support moa engraft
potenti help correct vision halt vision loss retin pigmentosa
rp valu realli small concept correct vision
demonstr rel small valu gene therapi space
data review demonstr averag improv
letter equival read addit four line letter standard
etdr eye chart vs control eye
patient note qualit improv vision treat
eye result also meaning regulatori perspect
cell therapi fda guidanc gene therapi clinic meaning
improv retin disord letter baselin next cohort
initi dose patient greater visual acuiti baselin
reneuron expect effect hrpc could even pronounc
hrpc retin pigmentosa rp progenitor cell hrpc abl
regener area retina engraft therapi subject
on-going studi patient enrol across three dose cohort
cell use cryopreserv formul import view
unlik gene therapi approach rp luxterna hrpc agnost
genet background thu applic larger rp popul posit
initi result portion report first dose cohort
portion trial use cryopreserv cell enrol subject
still retin function import distinct
sever popul patient retin structure/funct may repres
ideal popul cell therapi hrpc
data thu far phase rp result thu far earli stage
posit view three patient experienc improv visual acuiti
patient one letter baselin letter day letter day
patient two letter baselin day letter day
patient three letter baselin day letter day
averag improv letter equival read addit four line
standard etdr eye chart standard chart clinic trial retin disord
compar control eye rang importantli
result meet letter threshold clinic meaning accord
fda guidanc gene therapi retin disord patient note subject
improv treat eye dose second cohort patient greater
baselin visual acuiti on-going could demonstr even pronounc
model updat reduc risk adjust hrpc rp
also roll metric forward march made minor
adjust net result increas pt
click full note
maxim analyst coverag univers
